"Making PrEP available
without cost-sharing eliminates a major barrier to this landmark HIV prevention
tool. At a time when out-of-pocket costs are rising for patients as they seek
access to medications, this recommendation is a win both for patients and
public health."
— Michael
Ruppal, executive director of The AIDS Institute, spoke with AIS's RADAR on Specialty Pharmacy
about the U.S. Preventive Services Task Force (USPSTF)'s recent "A"
rating of preexposure prophylaxis (PrEP), the HIV prevention drug.
No comments:
Post a Comment